Regenxbio (RGNX) Misses Q3 EPS by 29c; Reports $533.5M of Cash and Cash Equivalents

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.37), $0.29 worse than the analyst estimate of ($1.08). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $41.46 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Faraday Future unveils nine robot models, prices start at $9,990
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy